Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07622095 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Validation of the French Version of the New Mobility Score (NMS)

Study acronym: MOB-SCORE
StatusRecruiting
PhaseNot specified
Started2026-08-27
View on ClinicalTrials.gov ↗

Amendment history

2026-09-01
notable
Study Status, Contacts/Locations v1
Recruitment opened
Primary completion date2028-01→2028-02
Completion date2028-02→2028-03
Start dateestimated 2026-07→confirmed 2026-08-27
Study sitesdetails revised at 1 of 1 site
2026-05-28
minor
Original filing
The incidence of hip fractures in France is 50,000 cases per year among women and 16,000 among men, with a 1-year mortality rate of 20-24%. After a fracture, 10-30% of patients become functionally dependent. The increasing aging of the population and the rise in dependency are likely to worsen the situation of older patients in hospital settings. Several tools are available to assess functional independence, including the New Mobility Score (NMS), which evaluates mobility through three domains: mobility indoors, mobility outdoors, and shopping activities. The NMS has shown good performance in predicting patient mortality and functional recovery, and its use is recommended in clinical practice. However, the French version of the NMS has not yet been validated. The French validation of the NMS is important to facilitate its implementation in clinical practice and research, particularly because of its simplicity and the need for rapid assessment tools for healthcare professionals. A French version of the NMS has been translated, and the MOB-SCORE study aims to assess its reliability and validity among healthcare professionals caring for patients with hip fractures.
Trial Details
NCT Number NCT07622095
Lead Sponsor Hospices Civils de Lyon
Conditions Hip Fractures, Mobility Limitation, Independence, Autonomy
Enrollment 100 participants
Start Date 2026-08-27
Primary Completion 2028-02 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-09-03